Drugs / Recombinant Human Chymotrypsin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06525272 | Jul 2024 → Jul 2025 overdue | pleurisy | Healthgen Biotechnology Corp. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06722664 | Dec 2024 → May 2025 overdue | stomach disorder | Healthgen Biotechnology Corp. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Chymotrypsin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06722664 ↗ |
| Known as | OsrhCT | “Investigational Drug: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, stored at 2-8°C.” NCT06525272 ↗1“Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder” NCT06722664 ↗ |
| Modality | Protein / enzyme biologic | “Investigational Drug: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, stored at 2-8°C.” NCT06525272 ↗ |
| Route | Other | “OsrhCT administered intrathoracically in single and multiple doses” NCT06525272 ↗ |